Skip to main content
Download PDF

Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Journal of Clinical Movement Disorders volume 7, Article number: 6 (2020) Cite this article

The Original Article was published on 11 February 2020

Correction to: J Clin Mov Disord 7, 2 (2020)

https://doi.org/10.1186/s40734-020-0083-0

Following publication of the original article [1], an error was identified in the Cost-per-responder sub-section.

The updated conclusion is given below and the changes have been highlighted in bold typeface.

The results showed that the adjusted mean total cost-per-responder was lower for patients receiving aboBoNT-A compared to patients receiving onaBoNT-A (€986 vs. €1524), based on the primary treatment response definition.

Reference

  1. Misra VP, Danchenko N, Maisonobe P, et al. Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord. 2020;7:2 https://doi.org/10.1186/s40734-020-0083-0.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imperial College Healthcare NHS Trust, London, UK

    V. P. Misra

  2. Ipsen, Boulogne–Billancourt, France

    N. Danchenko & P. Maisonobe

  3. Ipsen, Stockholm, Sweden

    J. Lundkvist

  4. ICON plc, Munich, Germany

    M. Hunger

Authors
  1. V. P. Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Danchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Maisonobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Lundkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Hunger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Danchenko.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Misra, V.P., Danchenko, N., Maisonobe, P. et al. Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord 7, 6 (2020). https://doi.org/10.1186/s40734-020-00088-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s40734-020-00088-5

Journal of Clinical Movement Disorders

ISSN: 2054-7072

Contact us